Section 01: Executive Summary
Clinical Trial Navigator • Strategic Viability Report
⚙️ VERDICT: PROTOTYPE FIRST
Strong market fit with high social impact, but requires validation of AI translation accuracy and B2B willingness-to-pay.
The Essence
Clinical Trial Navigator is a mobile-first AI platform that demystifies clinical trial discovery for patients and caregivers, translating complex medical jargon into actionable, life-saving opportunities while solving the $2B recruitment bottleneck for pharma.
Core Problem Solved
The Discovery Bottleneck: Over 450,000 clinical trials exist globally, yet 80% fail to enroll on time. Patients facing life-threatening conditions are lost in a sea of medical jargon on government databases.
The Cost: This delay costs the industry billions and, more critically, denies patients access to cutting-edge treatments. Current solutions are built for researchers, not humans, resulting in missed opportunities and emotional exhaustion for families.
Primary Audience
Who: Patients with chronic/serious conditions (cancer, rare diseases, autoimmune) and their caregivers. Highly motivated, digitally literate, and overwhelmed.
Why Now: Post-COVID, patients are more active participants in their healthcare journey. There is a growing "consumerization" of health data, with 50M+ Americans seeking alternatives to standard care.
Market Size Breakdown
Why Now?
🤖 AI Readiness
Large Language Models (LLMs) have reached the maturity required to accurately parse complex medical eligibility criteria into plain language, a technical impossibility just 2 years ago.
📈 Data Interoperability
Widespread FHIR adoption and Apple HealthKit integration make importing patient health records for automated matching technically feasible and scalable.
⏳ Industry Crisis
Pharma is desperate for solutions to the 6-month average recruitment delay, creating a high-willingness-to-pay B2B environment for qualified leads.
Competitive Positioning
Navigator occupies the "Sweet Spot": High trust/accuracy data combined with consumer-grade user experience.
Top 3 Highlights
Using LLMs to translate complex eligibility criteria into plain language is the "killer feature." It instantly removes the primary barrier to entry for non-medical users, creating immediate value and stickiness.
Unlike pure consumer plays, this business has a clear path to B2B revenue. Pharma companies spend heavily on patient recruitment; providing qualified, intent-rich leads is a high-value service.
The user base (chronic condition patients) is highly networked in online communities. A product that genuinely helps them find hope will generate organic, word-of-mouth growth that money can't buy.
Overall Viability Scores
Critical Success Factors
- ✓ AI Accuracy > 95%: Trust is the currency. Hallucinations in medical data are fatal to the product.
- ✓ Community Integration: Must become the default tool in rare disease Facebook groups/forums.
- ✓ B2B Validation: Securing 1-2 LOIs from Pharma partners before full build.
Key Risks & Mitigations
Mitigation: Aggressive disclaimers, UX designed as "information navigator" not "diagnostic tool," legal review of all copy.
Mitigation: Scrape data diversification strategy; build direct relationships with hospital systems for FHIR data.
Mitigation: Compassionate UX design, clear status indicators ("Not Recruiting"), counselor resources integration.
Success Metrics (First 6 Months)
Recommended Next Steps
- Week 1-2: Conduct 20 deep-dive interviews with oncology/rare disease patients to map the "journey of confusion."
- Week 3: Launch "Wizard of Oz" landing page (manual matching) to test willingness to share health data.
- Week 4-6: Build AI prototype to parse "Eligibility Criteria" from 100 top trials and measure accuracy against clinician review.
- Week 7-8: Secure 3 Letters of Intent (LOI) from CROs or Pharma patient recruitment heads.
- Week 9-12: Develop MVP (Mobile PWA) with core matching and plain-language summary features.